Autopsy report · NCT02793765

Docetaxel Followed by Provenge in Metastatic Prostate Cancer

“Dendreon was sold and new company decided not to fund study.”

The sponsor’s own words in the registry.

Life of this trial

• Withdrawn before it enrolled anyone. Its dates are the sponsor's plans, not events that happened.

Vital statistics

Status

Withdrawn

Phase

Phase 2

Sponsor

The University of Texas Health Science Center, Houston

Sponsor type

University, hospital or other

Conditions

Prostate Cancer

Interventions

Docetaxel; Sipuleucel-T

Participants

0

Sites

1

Countries

United States

Trials that died the same way

• Manual Therapy/Exercises vs. Physiotherapy/Back School vs. Waiting List in Patients With Chronic Low Back Pain
  “Sponsor did not want to continue the study.” (65% match in meaning)
• Impact of Nutrition and Swallowing Function of Head and Neck Cancer Patients During the Course of Treatment
  “The study did not receive funding.” (64% match in meaning)
• Coping Effectiveness Training for ALS
  “The study was not funded.” (63% match in meaning)
• Improving Relationships Using Motivational Interviewing
  “The research study was not funded.” (62% match in meaning)
• UCLA Couples Counseling for Combat Veterans
  “Proposed studies were not funded” (61% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.